Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antiviral agents"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 66071
Tytuł:
Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus .
Autorzy:
Cross RW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Woolsey C; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Chu VC; Gilead Sciences, Inc., Foster City, CA, USA.
Babusis D; Gilead Sciences, Inc., Foster City, CA, USA.
Bannister R; Gilead Sciences, Inc., Foster City, CA, USA.
Vermillion MS; Gilead Sciences, Inc., Foster City, CA, USA.
Geleziunas R; Gilead Sciences, Inc., Foster City, CA, USA.
Barrett KT; Gilead Sciences, Inc., Foster City, CA, USA.
Bunyan E; Gilead Sciences, Inc., Foster City, CA, USA.
Nguyen AQ; Gilead Sciences, Inc., Foster City, CA, USA.
Cihlar T; Gilead Sciences, Inc., Foster City, CA, USA.
Porter DP; Gilead Sciences, Inc., Foster City, CA, USA.
Prasad AN; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Deer DJ; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Borisevich V; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Agans KN; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Martinez J; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Harrison MB; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Dobias NS; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Fenton KA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Bilello JP; Gilead Sciences, Inc., Foster City, CA, USA.
Geisbert TW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Mar 15; Vol. 383 (6688), pp. eadk6176. Date of Electronic Publication: 2024 Mar 15.
Typ publikacji:
Journal Article
MeSH Terms:
Ebolavirus*/drug effects
Hemorrhagic Fever, Ebola*/drug therapy
Hemorrhagic Fever, Ebola*/prevention & control
Nucleosides*/administration & dosage
Nucleosides*/pharmacology
Alanine*/administration & dosage
Alanine*/analogs & derivatives
Alanine*/pharmacology
Prodrugs*/administration & dosage
Prodrugs*/pharmacology
Antiviral Agents*/administration & dosage
Antiviral Agents*/pharmacology
Animals ; Administration, Oral ; Macaca fascicularis ; Adenosine Monophosphate/administration & dosage ; Adenosine Monophosphate/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An oral antiviral for Ebola disease.
Autorzy:
Sprecher A; Médecins Sans Frontières, Brussels, Belgium.
Van Herp M; Médecins Sans Frontières, Brussels, Belgium.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Mar 15; Vol. 383 (6688), pp. 1181-1182. Date of Electronic Publication: 2024 Mar 14.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/administration & dosage
Antiviral Agents*/pharmacology
Ebolavirus*/drug effects
Hemorrhagic Fever, Ebola*/drug therapy
Prodrugs*/administration & dosage
Prodrugs*/pharmacology
Humans ; Administration, Oral ; Animals
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting host-virus interactions: in silico analysis of the binding of human milk oligosaccharides to viral proteins involved in respiratory infections.
Autorzy:
Mahaboob Ali AA; Gene Therapy Laboratory, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, 632 014, India.
Vishal A; Gene Therapy Laboratory, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, 632 014, India.
Nelson EJR; Gene Therapy Laboratory, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, 632 014, India. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 19; Vol. 14 (1), pp. 4111. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/pharmacology
Antiviral Agents*/chemistry
Influenza, Human*
Humans ; Viral Proteins ; Molecular Docking Simulation ; Milk, Human ; SARS-CoV-2 ; Oligosaccharides
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Recent Advances on Targeting Proteases for Antiviral Development.
Autorzy:
Borges PHO; Laboratory of Organic Synthesis and Biological Prospecting, Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-909, Brazil.; Laboratory of Experimental and Computational Biochemistry of Drugs, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Ferreira SB; Laboratory of Organic Synthesis and Biological Prospecting, Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-909, Brazil.
Silva FP Jr; Laboratory of Experimental and Computational Biochemistry of Drugs, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Feb 27; Vol. 16 (3). Date of Electronic Publication: 2024 Feb 27.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Peptide Hydrolases*/metabolism
Antiviral Agents*/therapeutic use
Humans ; Endopeptidases ; SARS-CoV-2/metabolism ; Viral Proteases
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Autorzy:
Nishikawa T; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Matsui M; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Onishi S; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Ushiro K; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Asai A; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Kim SK; Department of Gastroenterology, Kobe Asahi Hospital, Kobe 653-8501, Japan.
Nishikawa H; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 13; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/adverse effects
Hepatitis B, Chronic*/drug therapy
Humans ; Middle Aged ; Tenofovir/adverse effects ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; DNA, Viral ; Alanine/therapeutic use ; Adenine/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Functional Implications of Broad Spectrum Bioactive Compounds Targeting RNA-Dependent RNA Polymerase (RdRp) in the Context of the COVID-19 Pandemic.
Autorzy:
Comunale BA; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Larson RJ; Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.; Department of Palliative Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Jackson-Ward E; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.; Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Singh A; Department of Biological Sciences, University of California San Diego, La Jolla, CA 92161, USA.
Koback FL; Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
Engineer LD; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.; Department of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Nov 25; Vol. 15 (12). Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Antiviral Agents*/metabolism
COVID-19*/genetics
COVID-19*/metabolism
RNA-Dependent RNA Polymerase*/drug effects
RNA-Dependent RNA Polymerase*/genetics
Humans ; Membrane Proteins ; Molecular Docking Simulation ; Pandemics ; SARS-CoV-2/metabolism ; COVID-19 Drug Treatment/methods
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.
Autorzy:
Nguyen BT; Université Paris Cité, INSERM, IAME, F-75018, Paris, France.
Marc A; Université Paris Cité, INSERM, IAME, F-75018, Paris, France.
Suñer C; Skin Neglected Diseases and Sexually Transmitted Infections Section, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.; Fight Infectious Diseases Foundation, Badalona, Spain.
Marks M; Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Hospital for Tropical Diseases, London, United Kingdom.; Division of Infection and Immunity, University College London, London, United Kingdom.
Ubals M; Skin Neglected Diseases and Sexually Transmitted Infections Section, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.; Fight Infectious Diseases Foundation, Badalona, Spain.; Facultat de Medicina, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
Hernández-Rodríguez Á; Microbiology Department, Clinical Laboratory North Metropolitan Area, University Hospital Germans Trias I Pujol, Badalona, Spain.; Department of Genetics and Microbiology, Autonomous University of Barcelona, Barcelona, Spain.
Melendez MÁ; Microbiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Hruby DE; SIGA Technologies, Inc., Corvallis, Oregon, United States of America.
Russo AT; SIGA Technologies, Inc., Corvallis, Oregon, United States of America.
Mentré F; Université Paris Cité, INSERM, IAME, F-75018, Paris, France.; Unité de Recherche Clinique, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.
Mitjà O; Skin Neglected Diseases and Sexually Transmitted Infections Section, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.; Fight Infectious Diseases Foundation, Badalona, Spain.; Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain.; School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea.
Grosenbach DW; SIGA Technologies, Inc., Corvallis, Oregon, United States of America.
Guedj J; Université Paris Cité, INSERM, IAME, F-75018, Paris, France.
Pokaż więcej
Corporate Authors:
Movie Group
Źródło:
PLoS biology [PLoS Biol] 2023 Dec 21; Vol. 21 (12), pp. e3002249. Date of Electronic Publication: 2023 Dec 21 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Mpox (monkeypox)*
Animals ; Humans ; Benzamides ; Isoindoles/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments.
Autorzy:
Colomer-Castell S; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Gregori J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Garcia-Cehic D; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.
Riveiro-Barciela M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Buti M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Rando-Segura A; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Vico-Romero J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Campos C; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Ibañez-Lligoña M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Adombi CM; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Institute of Agropastoral Management, University Peleforo Gon Coulibaly, Korhogo BP 1328, Côte d'Ivoire.
Cortese MF; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Tabernero D; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Esteban JI; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Rodriguez-Frias F; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Quer J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 06; Vol. 24 (24). Date of Electronic Publication: 2023 Dec 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Hepatitis E virus*/genetics
Humans ; Mutagens ; Quasispecies/genetics ; Ribavirin/pharmacology ; Ribavirin/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
Autorzy:
Zhou Z; Department of Respiratory and Critical Care Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, The First Hospital of Changsha, Changsha, Hunan, China.
Zheng H; Department of Infectious Disease, The Central Hospital of Shaoyang, Shaoyang, Hunan, China.
Xiao G; Department of Infectious Disease, The Central Hospital of Shaoyang, Shaoyang, Hunan, China.
Xie X; Department of Infectious Disease, The Central Hospital of Shaoyang, Shaoyang, Hunan, China.
Rang J; Department of Nursing, The First Hospital of Changsha, Changsha, Hunan, China. .
Peng D; Department of Infectious Disease, The Central Hospital of Shaoyang, Shaoyang, Hunan, China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2024 Jan 04; Vol. 24 (1), pp. 47. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Antiviral Agents*/adverse effects
COVID-19*
COVID-19 Drug Treatment*
Aged ; Humans ; Retrospective Studies ; Ritonavir
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
In-silico evaluation of natural alkaloids against the main protease and spike glycoprotein as potential therapeutic agents for SARS-CoV-2.
Autorzy:
Shah M; Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Yamin R; Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Ahmad I; Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Wu G; Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Jahangir Z; Department of Computer Science, University of Agriculture Faisalabad, Punjab, Pakistan.
Shamim A; Department of Computer Science, University of Agriculture Faisalabad, Punjab, Pakistan.
Nawaz H; Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Nishan U; Department of Chemistry, Kohat University of Science & Technology, Kohat, Pakistan.
Ullah R; Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Ali EA; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Sheheryar; Department of Biochemistry and Molecular Biology, Federal University of Ceara, Fortaleza, Brazil.
Chen K; Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Jan 04; Vol. 19 (1), pp. e0294769. Date of Electronic Publication: 2024 Jan 04 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Alkaloids*/pharmacology
Antiviral Agents*/pharmacology
Protease Inhibitors*/pharmacology
SARS-CoV-2*/drug effects
Spike Glycoprotein, Coronavirus*/antagonists & inhibitors
Humans ; COVID-19 ; Emetine ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Peptide Hydrolases
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost-effectiveness of tenofovir alafenamide and entecavir in chronic hepatitis B in Saudi Arabia.
Autorzy:
Al-Jedai A; Assistant Deputy Minister for Medical Support Services, Riyadh, Saudi Arabia.; Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia.; Professor, Colleges of Medicine and Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.; Consultant Clinical Pharmacist, Solid Organ Transplant, Riyadh, Saudi Arabia.
Pokaż więcej
Źródło:
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2024 Jan 01; Vol. 30 (1), pp. 1-3. Date of Electronic Publication: 2024 Jan 08.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/epidemiology
Tenofovir*/analogs & derivatives
Tenofovir*/therapeutic use
Antiviral Agents*/therapeutic use
Humans ; Cost-Benefit Analysis ; Saudi Arabia/epidemiology ; Alanine/therapeutic use ; Guanine/analogs & derivatives ; Guanine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Maribavir: Mechanism of action, clinical, and translational science.
Autorzy:
Sun K; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Fournier M; Clinical Sciences, Rare Genetics & Hematology Therapeutic Area Unit, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Sundberg AK; Clinical Sciences, Rare Genetics & Hematology Therapeutic Area Unit, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Song IH; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13696.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*
Cytomegalovirus Infections*/chemically induced
Cytomegalovirus Infections*/drug therapy
Dichlororibofuranosylbenzimidazole/*analogs & derivatives
Humans ; Translational Science, Biomedical ; Benzimidazoles
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effective Antiviral Application of Antisense in Plants by Exploiting Accessible Sites in the Target RNA.
Autorzy:
Gruber C; Institute of Biochemistry and Biotechnology, Section Microbial Biotechnology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany.
Gursinsky T; Institute of Biochemistry and Biotechnology, Section Microbial Biotechnology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany.
Gago-Zachert S; Institute of Biochemistry and Biotechnology, Section Microbial Biotechnology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany.
Pantaleo V; Institute for Sustainable Plant Protection, Department of Biology, Agricultural and Food Sciences National Research Council, Bari Unit, I-70126 Bari, Italy.
Behrens SE; Institute of Biochemistry and Biotechnology, Section Microbial Biotechnology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 05; Vol. 24 (24). Date of Electronic Publication: 2023 Dec 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/pharmacology
RNA Interference ; RNA, Small Interfering/metabolism ; RNA, Messenger/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The hope and hype of ellagic acid and urolithins as ligands of SARS-CoV-2 Nsp5 and inhibitors of viral replication.
Autorzy:
Bianconi E; Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Gidari A; Department of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, Perugia, Italy.
Souma M; Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Sabbatini S; Medical Microbiology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Grifagni D; Centre for Magnetic Resonance, University of Florence, Sesto Fiorentino, Italy.; Department of Chemistry, University of Florence, Sesto Fiorentino, Italy.
Bigiotti C; Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Schiaroli E; Department of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, Perugia, Italy.
Comez L; Istituto Officina dei Materiali-IOM, National Research Council-CNR, Perugia, Italy.
Paciaroni A; Department of Physics and Geology, University of Perugia, Perugia, Italy.
Cantini F; Centre for Magnetic Resonance, University of Florence, Sesto Fiorentino, Italy.; Department of Chemistry, University of Florence, Sesto Fiorentino, Italy.
Francisci D; Department of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, Perugia, Italy.
Macchiarulo A; Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2251721.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/pharmacology
Biological Products*/pharmacology
Ellagic Acid*/pharmacology
SARS-CoV-2*/drug effects
Virus Replication*/drug effects
Heterocyclic Compounds/pharmacology ; Ligands
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Recent progress in discovery of novel AAK1 inhibitors: from pain therapy to potential anti-viral agents.
Autorzy:
Yuan YH; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Mao ND; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Duan JL; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Zhang H; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.; School of Basic Medical Science, Hangzhou Normal University, Hangzhou, China.
Garrido C; INSERM UMR 1231, Labex LipSTIC, University of Bourgogne, Dijon, France.; Cancer Center George François Leclerc, Dijon, France.; University of Bourgogne Franche-Comté, Besançon, France.
Lirussi F; INSERM UMR 1231, Labex LipSTIC, University of Bourgogne, Dijon, France.; University of Franche-Comté & University Hospital of Besançon, Besancon, France.
Gao Y; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.; Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xie T; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Ye XY; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2279906. Date of Electronic Publication: 2023 Nov 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Protein Serine-Threonine Kinases*
Antiviral Agents*/pharmacology
Humans ; Phosphorylation ; Pain
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.
Autorzy:
Aboul-Fotouh S; Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.; Clinical Pharmacology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mahmoud AN; Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Elnahas EM; Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Habib MZ; Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. .
Abdelraouf SM; Department of Biochemistry, Faculty of Pharmacy, Misr International University, Cairo, Egypt.
Pokaż więcej
Źródło:
Virology journal [Virol J] 2023 Oct 24; Vol. 20 (1), pp. 241. Date of Electronic Publication: 2023 Oct 24.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/therapeutic use
Antiviral Agents*/pharmacology
COVID-19*
Humans ; SARS-CoV-2 ; Antibodies, Viral ; Antibodies, Monoclonal
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Current Perspectives in Antiviral Research.
Autorzy:
Tarasova OA; Laboratory of Structure-Function Based Drug Design, Institute of Biomedical Chemistry, 10 Bldg. 8, Pogodinskaya Str., 119121 Moscow, Russia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Sep 26; Vol. 24 (19). Date of Electronic Publication: 2023 Sep 26.
Typ publikacji:
Editorial
MeSH Terms:
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Host-Pathogen Interactions*
Virus Replication
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities.
Autorzy:
Manna S; Department of Chemistry, Visvesvaraya National Institute of Technology, Nagpur 440010, India.
Das K; Department of Chemistry, Visvesvaraya National Institute of Technology, Nagpur 440010, India.
Santra S; Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute, Ural Federal University, 19 Mira Street, 620002 Yekaterinburg, Russia.
Nosova EV; Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute, Ural Federal University, 19 Mira Street, 620002 Yekaterinburg, Russia.; I. Ya. Postovskiy Institute of Organic Synthesis, Ural Division of the Russian Academy of Sciences, 22 S. Kovalevskoy Street, 620219 Yekaterinburg, Russia.
Zyryanov GV; Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute, Ural Federal University, 19 Mira Street, 620002 Yekaterinburg, Russia.; I. Ya. Postovskiy Institute of Organic Synthesis, Ural Division of the Russian Academy of Sciences, 22 S. Kovalevskoy Street, 620219 Yekaterinburg, Russia.
Halder S; Department of Chemistry, Visvesvaraya National Institute of Technology, Nagpur 440010, India.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Aug 28; Vol. 15 (9). Date of Electronic Publication: 2023 Aug 28.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/pharmacology
Drug Discovery*
Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Covalent Inhibitors from Saudi Medicinal Plants Target RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2.
Autorzy:
Bakheit AH; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Saquib Q; Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Ahmed S; Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Ansari SM; Botany & Microbiology Department, College of Sciences, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Al-Salem AM; Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Al-Khedhairy AA; Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Oct 30; Vol. 15 (11). Date of Electronic Publication: 2023 Oct 30.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/pharmacology
Plants, Medicinal*/chemistry
RNA-Dependent RNA Polymerase*/antagonists & inhibitors
SARS-CoV-2*/drug effects
Amino Acids ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Saudi Arabia
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 66071

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies